Follow the Pacific Health Care Organization INC stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Pacific Health Care Organization INC has recorded 33 public disclosures. Market capitalisation: €14m. The latest transaction was reported on 28 June 2024 (Acquisition). Among the most active insiders: KUBOTA TOM. Every trade is accessible without an account.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 33 declarations
Pacific Health Care Organization, Inc. (PFHO) is a small U.S. healthcare-services company listed in the United States on the OTCQB market, not on NYSE or NASDAQ at present. For French-speaking investors, PFHO is best understood as a niche workers’ compensation cost-containment specialist focused on California employers and claims administrators. The company’s core value proposition is to help manage medical spend and administrative complexity in workers’ compensation cases. Its principal office is in Irvine, California, United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1138476/000118518525000193/pacifichco10k123124.htm?utm_source=openai)) PFHO’s corporate history dates back to 1970, when it was incorporated in Utah as Clear Air, Inc. The company adopted the name Pacific Health Care Organization, Inc. in January 2001, marking a strategic shift into healthcare cost containment. A key milestone followed in February 2001 with the acquisition of Medex Healthcare, Inc., a California company founded in 1994. Medex remains central to the group’s operating model and manages Health Care Organizations (HCOs) and Medical Provider Networks (MPNs) in California. PFHO later added MMC, which oversees bill review and utilization review, and MMM, which handles medical case management and employee advocate services. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001138476/000118518526000897/pfho10k123125.htm?utm_source=openai)) From a business-line perspective, PFHO is not a diversified healthcare provider; it is a specialized service company. Its principal offerings include HCO administration, MPN administration, medical bill review, utilization review, medical case management, and related workers’ compensation support services. This mix positions the company along the claims-management and cost-control chain rather than in direct patient care. The company also disclosed that it discontinued lien representation services in the third quarter of 2023 because demand was insufficient. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001138476/000118518526000897/pfho10k123125.htm?utm_source=openai)) Competitively, PFHO occupies a narrow but defensible niche. Its scale is modest, and its geographic footprint is concentrated mainly in California, which makes the business highly dependent on local workers’ compensation dynamics, provider relationships, and regulatory conditions. That concentration can support specialization, but it also creates customer concentration risk. In its 2023 filing, the company disclosed that a few major customers accounted for a meaningful share of sales, reinforcing the microcap profile and the importance of account retention. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1138476/000118518524000392/pacifichco20231231_10k.htm?utm_source=openai)) Recent developments show a still-operating, small-cap company rather than a high-growth story. PFHO’s SEC filings indicate continued activity through 2024 and 2025, and the company reported full-year 2025 revenue of $6.72 million versus $6.07 million in 2024, helped by growth in medical case management and utilization review. For investors following SEC Form 4 insider transactions, the name is also relevant because insider filing activity can be a useful sentiment signal in microcap equities, especially when trading liquidity is limited. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001138476/000118518526000897/pfho10k123125.htm?utm_source=openai))